Skip to main navigation
logo
  • Overview
  • Corporate
    • Corporate Profile
    • Management
    • Board of Directors
    • Key Advisors
    • Corporate Governance
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Quarterly Results
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • IR Contacts

News & Events

News Releases

News Releases

  • All
  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
2021.03.29
Adagene Announces Clinical Advancement for ADG116
2021.03.16
Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program
2021.02.11
Adagene Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option
2021.02.09
Adagene Inc. Announces Pricing of Initial Public Offering
2021.02.01
Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Current page 19
  • Page 20
  • Page 21
  • Next page next ›
  • Last page last »
Displaying 91 - 95 of 105

Shareholder Tools

  • © 2026 Adagene Inc.

Footer Bottom

  • Home
  • Privacy
  • Terms of Use
  • Contact
  • Site Credits
  • LinkedIn